Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership


Sarepta Therapeutics Inc SRPT will pay GenEdit up to $57 million in the near term for access to the biotech's non-viral delivery platform for gene-editing therapies. 

  • Sarepta will combine its gene-editing technology with GenEdit's NanoGalaxy platform to target up to four neuromuscular indications selected by Sarepta. 
  • The tie-up comes after Sarepta dumped a gene therapy for a neurodegenerative disorder in partnership with Lysogene a few weeks ago. 
  • Sarepta is attempting to add to its gene-editing pipeline through collaboration with GenEdit.
  • Initial in vivo results have demonstrated the potential of GenEdit's polymer nanoparticles to deliver therapeutic cargo to specific muscle tissue for targeted, non-viral systemic delivery of genetic medicines. 
  • The research collaboration and option agreement commenced in December 2020.
  • GenEdit is also eligible for milestone payments and tiered royalties ranging from upper-single to low-double digits on future product sales. 
  • Additional financial details were not disclosed.
  • Price Action: SRPT shares are trading 1.73% higher at $72.81 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefsGene Editing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!